Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- SELF-MEDICATION NEWS IN BRIEF
June 16, 2008
- Changing Paradigm for Sales and Marketing Growing Markets for High- and Low-priced Drugs -2-
June 16, 2008
- STOP PRESS／Daiichi Sankyo to Acquire Majority of Ranbaxy Shares
June 16, 2008
- Daiichi Sankyo to Enter Oncology Field in Earnest by Acquiring U3 Pharma
June 16, 2008
- Combined Sales Exceed \6 Tril. Mark for 23 TSE 1st Section Companies
June 9, 2008
- TOPICS：Mr Kise of ATOL Elected President of Wholesalers' Fair Trade Council
June 9, 2008
- BUSINESS RESULTS
June 9, 2008
- Combined Sales of 4 Top Wholesalers Exceed \6 Tril.
June 9, 2008
- Teijin to Defend Top Market Share for Drugs for Osteoporosis: Mr Nishikawa
June 9, 2008
- Marketing Excellence Japan 2008
June 9, 2008
- Erbitux, Thymoglobulin, Mycobutin Recommended for Approval
June 9, 2008
- FJPWA Sets Common Goal for Price Agreement Rate at 70% by End Sept.
June 9, 2008
- Galderma's Adapalene, INO Therapeutics' Inoflow Recommended for Approval
June 9, 2008
- NPhA Members Exchange Opinions with Major Wholesalers
June 9, 2008
- Approval Recommended for OTC Version of Miconazole for Vaginal Candidiasis
June 9, 2008
- BUSINESS NEWS IN BRIEF
June 9, 2008
- Departure of Global Companies from Japan Is Serious Problem: Mr Yagi
June 9, 2008
- Top 4 Generic Makers' Combined Sales Up 9.4% to \138.9 Bil.
June 9, 2008
- DVx's Excimer Laser Lead Withdrawal System Recommended for Approval
June 9, 2008
- Sawai: Sales Up 9.7% with Double-digit Fall in Profits
June 9, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…